Non-melanoma skin cancer in patients with atopic dermatitis treated with topical tacrolimus

Journal of Dermatological Treatment

Volumn 16, Issue 3, 2005, Pages 149-153

  Naylor, Mark ^a   Elmets, Craig ^b   Jaracz, Eileen ^c   Rico, M Joyce ^c  

^a Oklahoma University Health Sciences Center   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

Atopic dermatitis; Non melanoma skin cancer; Tacrolimus ointment

Indexed keywords

TACROLIMUS;

ADOLESCENT; ADULT; AGED; ARTICLE; ATOPIC DERMATITIS; CANCER RISK; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EXPOSURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SKIN CANCER;

ADMINISTRATION, TOPICAL; ADULT; AGED; DERMATITIS, ATOPIC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; OINTMENTS; SKIN NEOPLASMS; TACROLIMUS; TREATMENT OUTCOME;

EID: 25444475018     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630510041088     Document Type: Article

References (33)

1. American Cancer Society: Cancer facts and figures 2002. Atlanta, GA: American Cancer Society, 2002.
2. Miller DL, Weinstock MA. Nonmelanoma skin cancer in the United States: Incidence. J Am Acad Dermatol. 1994;30:774-8.
3. Alam M, Ratner D. Cutaneous squamous-cell carcinoma. N Engl J Med. 2001;344:975-83.
4. Kuijpers DIM, Thissen MRTM, Neuman MHA. Basal cell carcinoma: treatment options and prognosis, a scientific approach to a common malignancy. Am J Clin Dermatol. 2002;3:247-59.
5. Berg D, Otley CC. Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. J Am Acad Dermatol. 2002;47:1-17.
6. Palier A, Eichenfield LF, Leung DYM, Stewart D, Appell M. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol. 2001;44(1 Suppl):S47-S57.
7. Hanifin JM, Ling MR, Langley R, Breneman D, Rafal E. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. J Am Acad Dermatol. 2001;44(1 Suppl):S28-S38.
8. Soter NA, Fleischer AB, Webster GF, Monroe E, Lawrence I. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. J Am Acad Dermatol. 2001;44(1 Suppl):S39-S46.
9. Kang S, Lucky AW, Pariser D, Lawrence I, Hanifin JM. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol. 2001;44(1 Suppl):S58-S64.
10. Naylor M, Elmets CA, Rico MJ, Zheng S. Treatment with topical tacrolimus is not associated with an increase in non-melanoma skin cancers. Poster presented at the 60th Annual Meeting of the American Academy of Dermatology, New Orleans, LA, 22-27 February 2002: P18.
11. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stockh). 1980;92:44-7.
12. Rajka G, Langeland T. Grading of the severity of atopic dermatitis. Acta Derm Venereol Suppl (Stockh). 1989;144:13-14.
13. Leemis LM, Trivedi KS. A comparison of approximate interval estimators for the Bernoulli Parameter. American Statistician. 1996;50:63-8.
14. Frieling UM, Schaumberg DA, Kupper TS, Muntwyler J, Hennekens CH. A randomized, 12-year primary-prevention trial of beta carotene supplementation for nonmelanoma skin cancer in the Physician's Health Study. Arch Dermatol. 2000;136:179-84.
15. Olesen AB, Engholm G, Storm HH, Thestrup-Pedersen K. Atopic dermatitis and the risk of cancer. J Invest Dermatol 2005 (in press).
16. Scotto J, Fears TR, Fraumeni JF. Incidence of non-melanoma skin cancer in the United States. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health, 1983. NIH Pub No. 83-2433.
17. Gellin GA, Kopf AW, Garfinkel L. Basal cell epithelioma. Arch Dermatol. 1965;91:38-45.
18. Harris RB, Grifith K, Moon TE. Trends in the incidence of nonmelanoma skin cancers in southeastern Arizona, 1985-1996. J Am Acad Dermatol. 2001;45:528-36.
19. Serrano H, Scotto J, Shornick G, Fears TR, Greenberg ER. Incidence of nonmelanoma skin cancer in New Hampshire and Vermont. J Am Acad Dermatol. 1991;24:574-9.
20. Bergstresser PR, Halprin KM. Multiple sequential skin cancers. The risk of skin cancer in patients with previous skin cancer. Arch Dermatol. 1975;111:995-6.
21. Marcil I, Stern RS. Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis. Arch Dermatol. 2000;136:1524-30.
22. Karagas MR, Stukel TA, Greenberg R, Baron JA, Mott LA, Stern RS. Risk of subsequent basal cell carcinoma and squamous cell carcinoma of the skin among patients with prior skin cancer. JAMA. 1992;267:3305-10.
23. Czarnecki D, Mar A, Staples M, Giles G, Meehan C. The development of non-melanocytic skin cancers in people with a history of skin cancer. Dermatology. 1994;189:364-7.
24. Schreiber MM, Moon TE, Fox SH, Davidson J. The risk of developing subsequent nonmelanoma skin cancers. J Am Acad Dermatol. 1990;23:1114-18.
25. Forman AB, Roenigk HH Jr, Caro WA, Magid ML. Long-term follow-up of skin cancer in the PUVA-48 cooperative study. Arch Dermatol. 1989;125:515-19.
26. Stern RS, Lange R. Non-melanoma skin cancer occurring in patients treated with PUVA five to ten years after first treatment. J Invest Dermatol. 1988;91:120-4.
27. Katz KA, Marcil I, Stern RS. Incidence and risk factors associated with a second squamous cell carcinoma or basal cell carcinoma in psoralen+ultraviolet A light-treated psoriasis patients. J Invest Dermatol. 2002;118:1038-43.
28. Marcil I, Stern RS. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet. 2001;358:1042-5.
29. Paul CF, Ho VC, McGeown C, Christophers E, Schmidtmann B, Guillaume JC, et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol. 2003;120:211-16.
30. Margolis D, Bilker W, Hennessy S, Vittorio C, Santanna J, Strom BL. The risk of malignancy associated with psoriasis. Arch Dermatol. 2001;137:778-83.
31. Ming ME, Levy R, Hoffstad O, Filip J, Abrams BB, Fernandez C, et al. The lack of a relationship between atopic dermatitis and nonmelanoma skin cancers. J Am Acad Dermatol. 2004;50:357-62.
32. Fleischer AB, Ling M, Eichenfield L, Satoi Y, Jaracz E, Rico MJ, et al. Tacrolimus ointment for the treatment of atopic dermatitis is not associated with an increase in cutaneous infections. J Am Acad Dermatol. 2002;47:562-70.
33. Hanifin JM, Paller AS, Eichenfield L, Clark RA, Korman N, Weinstein G, et al. Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis. J Am Acad Dermatol 2005 (in press).